



## **Ivacaftor**

**Catalog No: tcsc0497** 

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
<b>CAS No:</b> 873054-44-5
Formula: C <sub>24</sub> H <sub>28</sub> N <sub>2</sub> O <sub>3</sub>
Pathway: Membrane Transporter/Ion Channel
<b>Target:</b> CFTR
Purity / Grade: >98%
<b>Solubility:</b> H2O :
Alternative Names: VX-770
Observed Molecular Weight: 392.49





## **Product Description**

Ivacaftor is a potent and orally bioavailable **CFTR** potentiator, targeting G551D-CFTR and F508del-CFTR with **EC**<sub>50</sub>s of 100 nM and 25 nM, respectively.

IC50 & Target: EC50: 100 nM (G551D-CFTR), 25 nM (F508del-CFTR)<sup>[1]</sup>

In Vitro: Ivacaftor (10  $\mu$ M) increases the PC secretion activity by 3-fold for ABCB4-G535D, 13.7-fold for ABCB4-G536R, 6.7-fold for ABCB4-S1076C, 9.4-fold for ABCB4-S1176L, and 5.7-fold for ABCB4-G1178S. Ivacaftor corrects the functional defect of ABCB4 mutants<sup>[1]</sup>. Ivacaftor (10  $\mu$ M) significantly increases CFTR activity in W1282X-expressing cells compared to R1162X CFTR cells<sup>[2]</sup>. Ivacaftor shows no significant activity against 160 targets tested including the GABA<sub>A</sub> benzodiazepine receptor. Ivacaftor increases the chloride secretion with an EC<sub>50</sub> of 0.236  $\pm$  0.200  $\mu$ M, a 10-fold shift in potency compared to the F508del HBEs<sup>[3]</sup>. In recombinant cells, VX-770 increases CFTR channel open probability (Po) in both the F508del processing mutation and the G551D gating mutation. VX-770 increases forskolin-stimulated I<sub>T</sub> in temperature-corrected F508del-FRT cells by appr 6-fold with an EC<sub>50</sub> of 25 nM<sup>[4]</sup>.

In Vivo: Ivacaftor (1-200 mg/kg, p.o.) exhibits good oral bioavailability in rat<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!